Methods Mol Biol. 2021;2355:17-33. doi: 10.1007/978-1-0716-1617-8_3.

Peptide-Protein Conjugation and Characterization to Develop Vaccines for Group A Streptococcus.

Methods in molecular biology (Clifton, N.J.)

Sharareh Eskandari, Michael F Good, Manisha Pandey

PMID: 34386947 DOI: 10.1007/978-1-0716-1617-8_3

Abstract

Peptide conjugates have been widely used for developing vaccines that prevent common bacterial infections for which peptides alone are either ineffective or provide only short-term protection. Among several carrier proteins, diphtheria toxoid and CRM

© 2021. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.

Keywords: CRM197; Conjugate; Diphtheria toxoid; GAS; Group A streptococcus; Peptide; Protein; Vaccine

References

1. Liu H, Irvine DJ (2015) Guiding principles in the design of molecular bioconjugates for vaccine applications. Bioconjug Chem 26(5):791–801 - PubMed
2. Xu Z, Moyle PM (2017) Bioconjugation approaches to producing subunit vaccines composed of protein or peptide antigens and covalently attached toll-like receptor ligands. Bioconjug Chem 29(3):572–586 - PubMed
3. McCluskie MJ, Evans DM, Zhang N, Benoit M, McElhiney SP, Unnithan M et al (2016) The effect of preexisting anti-carrier immunity on subsequent responses to CRM197 or Qb-VLP conjugate vaccines. Immunopharmacol Immunotoxicol 38(3):184–196 - PubMed
4. Combadière B, Beaujean M, Chaudesaigues C, Vieillard V (2019) Peptide-based vaccination for antibody responses against HIV. Vaccine 7(3):105 - PubMed
5. Hayman WA, Brandt ER, Relf WA, Cooper J, Saul A, Good MF (1997) Mapping the minimal murine T cell and B cell epitopes within a peptide vaccine candidate from the conserved region of the M protein of group A streptococcus. Int Immunol 9(11):1723–1733 - PubMed
6. Dale JB, Batzloff MR, Cleary PP, Courtney HS, Good MF, Grandi G et al (2016) Current approaches to group A streptococcal vaccine development. In: Streptococcus pyogenes: basic biology to clinical manifestations [Internet]. University of Oklahoma Health Sciences Center, Oklahoma City - PubMed
7. Batzloff MR, Hayman WA, Davies MR, Zeng M, Pruksakorn S, Brandt ER et al (2003) Protection against group A streptococcus by immunization with J8-diphtheria toxoid: contribution of J8-and diphtheria toxoid-specific antibodies to protection. J Infect Dis 187(10):1598–1608 - PubMed
8. Reynolds S, Pandey M, Dooley J, Calcutt A, Batzloff M, Ozberk V et al (2021) Preclinical safety and immunogenicity of Streptococcus pyogenes (Strep A) peptide vaccines. 11(1):1–13 - PubMed
9.  Nordström T, Pandey M, Calcutt A, Powell J, Phillips ZN, Yeung G et al (2017) Enhancing Vaccine Efficacy by Engineering a Complex Synthetic Peptide To Become a Super Immunogen. J Immunol 199(8):2794–2802 - PubMed
10. Pandey M, Langshaw E, Hartas J, Lam A, Batzloff MR, Good MF (2015) A synthetic M protein peptide synergizes with a CXC chemokine protease to induce vaccine-mediated protection against virulent streptococcal pyoderma and bacteremia. J Immunol 194(12):5915–5925 - PubMed
11. Shinefield HR (2010) Overview of the development and current use of CRM197 conjugate vaccines for pediatric use. Vaccine 28(27):4335–4339 - PubMed
12. Lin FYC, Ho VA, Khiem HB, Trach DD, Bay PV, Thanh TC et al (2001) The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children. N Engl J Med 344(17):1263–1269 - PubMed
13. Rennels MB, Edwards KM, Keyserling HL, Reisinger KS, Hogerman DA, Madore DV et al (1998) Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM197 in United States infants. Pediatrics 101(4):604–611 - PubMed
14. Cooper B, DeTora L, Stoddard J (2011) Menveo - PubMed
15. Gill CJ, Baxter R, Anemona A, Ciavarro G, Dull P (2010) Persistence of immune responses after a single dose of Novartis meningococcal serogroup A, C, W-135 and Y CRM-197 conjugate vaccine (Menveo - PubMed
16. Giannini G, Rappuoli R, Ratti G (1984) The amino-acid sequence of two non-toxic mutants of diphtheria toxin: CRM45 and CRM197. Nucleic Acids Res 12(10):4063–4069 - PubMed
17. Mishra RP, Yadav RS, Jones C, Nocadello S, Minasov G, Shuvalova LA et al (2018) Structural and immunological characterization of E. coli derived recombinant CRM197 protein used as carrier in conjugate vaccines. Biosci Rep 38(5) - PubMed
18. Malito E, Bursulaya B, Chen C, Surdo PL, Picchianti M, Balducci E et al (2012) Structural basis for lack of toxicity of the diphtheria toxin mutant CRM197. Proc Natl Acad Sci 109(14):5229–5234 - PubMed
19. Bröker M, Costantino P, DeTora L, McIntosh ED, Rappuoli R (2011) Biochemical and biological characteristics of cross-reacting material 197 (CRM197), a non-toxic mutant of diphtheria toxin: use as a conjugation protein in vaccines and other potential clinical applications. Biologicals 39(4):195–204 - PubMed
20. Pandey M, Mortensen R, Calcutt A, Powell J, Batzloff MR, Dietrich J et al (2016) Combinatorial synthetic peptide vaccine strategy protects against hypervirulent CovR/S mutant streptococci. J Immunol 196(8):3364–3374 - PubMed
21. Pandey M, Powell J, Calcutt A, Zaman M, Phillips ZN, Ho MF et al (2017) Physicochemical characterisation, immunogenicity and protective efficacy of a lead streptococcal vaccine: progress towards phase I trial. Sci Rep 7(1):1–11 - PubMed
22. Caro-Aguilar I, Ottinger E, Hepler RW, Nahas DD, Wu C, Good MF et al (2013) Immunogenicity in mice and non-human primates of the group A Streptococcal J8 peptide vaccine candidate conjugated to CRM197. Hum Vaccin Immunother 9(3):488–496 - PubMed
23. Möginger U, Resemann A, Martin CE, Parameswarappa S, Govindan S, Wamhoff E-C et al (2016) Cross reactive material 197 glycoconjugate vaccines contain privileged conjugation sites. Sci Rep 6(1):1–13 - PubMed
24. Jalah R, Torres OB, Mayorov AV, Li F, Antoline JF, Jacobson AE et al (2015) Efficacy, but not antibody titer or affinity, of a heroin hapten conjugate vaccine correlates with increasing hapten densities on tetanus toxoid, but not on CRM197 carriers. Bioconjug Chem 26(6):1041–1053 - PubMed
25. Ellman GL (1959) Tissue sulfhydryl groups. Arch Biochem Biophys 82(1):70–77 - PubMed
26. Fagan V, Hussein WM, Su M, Giddam AK, Batzloff MR, Good MF et al (2017) Synthesis, characterization and immunological evaluation of self-adjuvanting group A streptococcal vaccine candidates bearing various lipidic adjuvanting moieties. ChemBioChem 18(6):545–553 - PubMed
27. Konigsberg W (1972) Reduction of disulfide bonds in proteins with dithiothreitol. Methods Enzymol 25:185–188 - PubMed
28. Leiro V, Parreira P, Freitas SC, Martins MCL, Pêgo AP (2018) Conjugation chemistry principles and surface functionalization of Nanomaterials. In: Biomedical applications of functionalized nanomaterials. Elsevier, pp 35–66 - PubMed
29. Henzel WJ, Stults JT (2001) Reversed-phase isolation of peptides. Curr Protoc Protein Sci 24(1):11.6.1–11.6.6 - PubMed
30. Crabb JW, West KA, Dodson WS, Hulmes JD (1997) Amino acid analysis. Current Protoc Protein Sci 7(1):11.9.1–11.9.42 - PubMed
31. Kabanova A, Adamo R, Proietti D, Berti F, Tontini M, Rappuoli R et al (2010) Preparation, characterization and immunogenicity of HIV-1 related high-mannose oligosaccharides-CRM 197 glycoconjugates. Glycoconj J 27(5):501–513 - PubMed

Publication Types

• Journal Article
• Research Support, Non-U.S. Gov't